加快我国药物创新发展的思考  

Thoughts on speeding up the pharmaceutical innovation in China

作　　者：顾金辉 GU Jin-hui(National Health Commission,Beijing 100191,China)

机构地区：[1]国家卫生健康委员会,北京100191

出　　处：《中国新药杂志》2023年第20期2009-2012,共4页Chinese Journal of New Drugs

摘　　要：党的十八大以来,我国医药创新发展不断取得新成就,新药研发正从跟随创新向原始创新加速转变。本文梳理了我国药物创新发展现状,分析存在的问题和制约因素,并提出对策建议。当前和今后一段时期我国药物创新面临的问题主要有:原始创新能力不足;部分产业链关键环节存在“断链”风险;缺乏具有全球竞争力的世界一流创新药企业等。针对资金、人才、技术、体系和政策环境存在的制约因素,提出发挥举国体制优势、提高创新投入效能、科技创新与人才工作协同推进、完善产学研医协同创新体系、优化医药创新生态与政策环境等思考建议。Achievements have been made in the development of pharmaceutical innovation in China since the Chinese Communist Party's 18th National Congress.China is moving toward from follow⁃on innovation to the original innovation.This paper reviews current situation of the drug innovation,analyzes the existing problems and obstacles,and puts forward corresponding suggestions.New challenges for the future of pharmaceutical innovation include lower innovative capability,risk of dependence on foreign technological in some key chains,lack of top pharmaceutical companies in the world,etc.Several suggestions for resolving these capital,talent,technology,system,and policy problems are proposed as follows:taking advantage of the new system for mobilizing resources nationwide,improving the efficiency of innovation investment,coordination of talent attraction policies and science and technology policies,developing industry⁃university⁃institute⁃hospital R&D,perfecting related policy and ecosystem environment.

关 键 词：药物创新 “重大新药创制”科技重大专项 科技创新 

分 类 号：R95[医药卫生—药学]